Otkrivanje lekova — разлика између измена

Uprkos napretka u tehnologiji i razumevanju bioloških sistema, proces otkrivanja lekova je još uvek dugotrajan, skup, težak, i neefikasan. Broj otkrića novih lekova je veoma mali.<ref name=Anson2009>{{Cite news | author1 = Anson, Blake D. | author2 = Ma, Junyi | author3 = He, Jia-Qiang | date = 1. 5. 2009. | title = Identifying Cardiotoxic Compounds | periodical = Genetic Engineering & Biotechnology News | series = TechNote | publisher = Mary Ann Liebert | volume = 29 | issue = 9 | pages = 34—35 | url = http://www.genengnews.com/articles/chitem_print.aspx?aid=2890&chid=0 | archiveurl = https://wwwweb.webcitationarchive.org/5iXZygEpu?url=web/20120921025805/http://www.genengnews.com/articles/chitem_print.aspx?aid=2890&chid=0 | archivedate = 2521. 0709. 20092012 | issn = 1935-472X | oclc = 77706455 | accessdate = 25. 7. 2009. | postscript = <!--None--> | dead-url = noyes | df = }}</ref> Trenutno su troškovi istraživanja i razvoja svakog [[novi molekulski entitet|novog molekulskog entiteta]] (NME) aproksimativno US $1,8 milijardi.<ref>{{cite journal | volume = 9 | pages = 203–214 | year = 2010 | doi = 10.1038/nrd3078 | title = How to improve R&D productivity: the pharmaceutical industry's grand challenge | author = Steven M. Paul, Daniel S. Mytelka, Christopher T. Dunwiddie, Charles C. Persinger, Bernard H. Munos, Stacy R. Lindborg & Aaron L. Schacht | journal = Nature Reviews Drug Discovery | pmid = 20168317 | issue = 3}}</ref>